Quent Capital LLC Sells 3,232 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Quent Capital LLC trimmed its holdings in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 76.7% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 983 shares of the biotechnology company's stock after selling 3,232 shares during the quarter. Quent Capital LLC's holdings in United Therapeutics were worth $347,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently bought and sold shares of the company. Newbridge Financial Services Group Inc. bought a new position in United Therapeutics during the 4th quarter valued at about $25,000. Brooklyn Investment Group bought a new position in shares of United Therapeutics during the 3rd quarter valued at approximately $33,000. Capital Performance Advisors LLP bought a new stake in shares of United Therapeutics during the 3rd quarter valued at $82,000. MassMutual Private Wealth & Trust FSB boosted its holdings in United Therapeutics by 31.9% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company's stock worth $85,000 after buying an additional 58 shares during the period. Finally, Values First Advisors Inc. purchased a new stake in United Therapeutics in the 3rd quarter worth $90,000. 94.08% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

UTHR has been the subject of a number of recent analyst reports. TD Cowen upped their price objective on United Therapeutics from $350.00 to $400.00 and gave the stock a "buy" rating in a research note on Monday, October 21st. HC Wainwright increased their price objective on shares of United Therapeutics from $400.00 to $425.00 and gave the company a "buy" rating in a report on Thursday, October 31st. UBS Group upped their target price on shares of United Therapeutics from $415.00 to $475.00 and gave the stock a "buy" rating in a research report on Wednesday, January 8th. Oppenheimer lifted their price target on shares of United Therapeutics from $575.00 to $600.00 and gave the company an "outperform" rating in a report on Thursday, October 31st. Finally, The Goldman Sachs Group raised their price objective on United Therapeutics from $243.00 to $302.00 and gave the company a "neutral" rating in a research report on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $382.08.

United Therapeutics Price Performance

Shares of NASDAQ:UTHR traded up $0.14 during trading on Friday, hitting $370.58. The company had a trading volume of 209,344 shares, compared to its average volume of 312,203. The stock has a market cap of $16.55 billion, a price-to-earnings ratio of 16.27, a price-to-earnings-growth ratio of 0.92 and a beta of 0.57. The company has a fifty day simple moving average of $361.93 and a two-hundred day simple moving average of $358.80. United Therapeutics Co. has a one year low of $211.61 and a one year high of $417.82.

Insider Buying and Selling

In other United Therapeutics news, COO Michael Benkowitz sold 10,000 shares of the company's stock in a transaction on Monday, February 10th. The stock was sold at an average price of $348.06, for a total value of $3,480,600.00. Following the transaction, the chief operating officer now owns 2,577 shares of the company's stock, valued at $896,950.62. This represents a 79.51 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Louis W. Sullivan sold 26,209 shares of United Therapeutics stock in a transaction on Wednesday, December 18th. The stock was sold at an average price of $373.22, for a total value of $9,781,722.98. Following the sale, the director now owns 5,051 shares of the company's stock, valued at approximately $1,885,134.22. This trade represents a 83.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 121,864 shares of company stock worth $44,516,965 over the last three months. 11.90% of the stock is owned by insiders.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.